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Abstract
CML is an hematopoietic stem cell disease characterized by the t(9;22) (q34;q11) translocation encoding the oncoprotein
p210BCR-ABL. The effect of acadesine (AICAR, 5-Aminoimidazole-4-carboxamide-1-b-D-ribofuranoside) a compound with
known antileukemic effect on B cell chronic lymphoblastic leukemia (B-CLL) was investigated in different CML cell lines.
Acadesine triggered loss of cell metabolism in K562, LAMA-84 and JURL-MK1 and was also effective in killing imatinib-
resistant K562 cells and Ba/F3 cells carrying the T315I-BCR-ABL mutation. The anti-leukemic effect of acadesine did not
involve apoptosis but required rather induction of autophagic cell death. AMPK knock-down by Sh-RNA failed to prevent
the effect of acadesine, indicating an AMPK-independent mechanism. The effect of acadesine was abrogated by GF109203X
and Ro-32-0432, both inhibitor of classical and new PKCs and accordingly, acadesine triggered relocation and activation of
several PKC isoforms in K562 cells. In addition, this compound exhibited a potent anti-leukemic effect in clonogenic assays
of CML cells in methyl cellulose and in a xenograft model of K562 cells in nude mice. In conclusion, our work identifies an
original and unexpected mechanism by which acadesine triggers autophagic cell death through PKC activation. Therefore,
in addition to its promising effects in B-CLL, acadesine might also be beneficial for Imatinib-resistant CML patients.
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Introduction
CML is a myeloproliferative syndrome linked to a hematopoi-
etic stem cell disorder leading to increased production of
granulocytes at all stages of differentiation [1]. CML patients
carry the t(9;22) (q34;q11) translocation [1], which is responsible
for the expression of p210 BCR-ABL, a constitutively active
tyrosine kinase [2]. The role of BCR-ABL in the pathogenesis of
CML is well documented [3,4]. Of note, BCR-ABL mediates
several survival pathways including STAT5/Bcl-xL, Ras/Raf/
MEK/Erk-1/2, PI3K/Akt and NF-kB, that collectively confer
proliferative advantages and resistance to apoptosis [5,6,7,8].
Imatinib (Gleevec) which targets the ATP-binding site of different
tyrosine kinases including BCR-ABL [9,10], selectively induces
growth arrest and apoptosis of BCR-ABL positive leukemia cells
with minimal effect on normal hematopoietic progenitors
[11,12,13].
AMP-activated protein kinase (AMPK) is a serine/threonine
protein kinase that regulates the intracellular AMP/ATP ratio and
participates in the regulation of glucose and lipid metabolism
[14,15]. Although Acadesine is commonly used as an AMPK
activator, there are compelling evidence in the literature that the
acadesine anti-tumoral effects could be not mediated by the
AMPK pathway [16,17,18]. Nevertheless, at present, the exact
nature of the AMPK-independent effects of acadesine in leukemic
cells is not understood.
In this study, we investigated the AMPK pathway as a possible
target for therapeutic intervention in CML patients. We found
that acadesine exerts a potent antileukemic effect in CML cell
lines either sensitive or resistant to Imatinib. Unexpectedly, the
acadesine anti-proliferative effect involved neither caspase
activation nor apoptosis. Moreover, whereas acadesine consis-
tently activated the AMPK pathway in CML cell lines, its anti-
proliferative effect was found to be independent on AMPK,
rather, activation of PKC was found to be required. Importantly,
the anti-leukemic effect of acadesine involved autophagy. To our
knowledge, our study provides the first evidence that acadesine
exerts its anti-leukemic through induction of autophagic cell
death. Finally, acadesine also inhibited tumor formation in a
xenograft model of CML in nude mice. Hence, acadesine may
find therapeutical application in Imatinib-resistant CML
patients.
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7889Materials and Methods
Reagents and Antibodies
RPMI 1640 medium and fetal calf serum (FCS) were purchased
from Gibco BRL (Paisley, UK). Sodium fluoride, orthovanadate,
phenylmethylsulfonyl fluoride, aprotinin and leupeptin were
purchased from Sigma (Saint-Louis, MO, USA). Ac-DEVD-
AMC, Z-RR-AMC, Ac-DEVD-CHO were purchased from Alexis
Biochemicals (Lausan, Switzerland). GF109293X (GFX) and Ro
32-0432 were from Tocris (Bristol, UK). Anti-SQSTM1, anti-
Actin, anti-Hsp90, anti-Hsp60 and anti-Abl antibodies were from
Santa Cruz Biotechnology (Tebu-Bio, Le Perray en Yvelines,
France). Anti-LC3B, anti-AMPK, anti-phospho-AMPK (Thr172),
anti-phospho-S6 Ribosomal Protein (Ser235/236), anti-S6 Ribo-
somal Protein, anti-phospho-Abl (Tyr245) and anti-phospho-Crkl
(Tyr207) were purchased from cell signalling technology (Danvers,
MA, USA). HRP conjugated anti-mouse, anti-rabbit and anti-goat
antibodies from Dakopatts (Glostrup, Denmark).
Cell Lines
The human CML K562, LAMA-84 and JURL-MK1 cell lines
were provided by ATCC and were grown at 37uC under 10%
CO2 in RPMI 1640 medium (Gibco BRL, Paisley, UK)
supplemented with 5% FCS (Gibco BRL, Paisley, UK) completed
with 50 units/ml penicillin, 50 mg/ml streptomycin and 1 mM
sodium pyruvate. Imatinib resistant K562 cells was described
earlier [19]. The Ba/F3 p210BCR/ABL WT and T31I cells were
kindly provided by Pr. FX Mahon and Pr. JV Melo.
Caspase 3 Activity Measurements
Caspase 3 assay has been described earlier [20,21].
Measurement of Cell Metabolism (XTT)
Cells (15610
3 cells/100 ml) were incubated with the effectors for
the times indicated. 50 ml of XTT reagent (sodium 39-[1-
(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro)
benzene sulfonic acid hydrate) was added to each well.
Absorbance of the formazan dye produced by metabolically active
cells was measured at 490 nm as described earlier [19]. Each assay
was performed in quadruplicate.
Western Blot
Western blot analysis have been described in details previously
[19].
Electronic Microscopy
K562 cell pellets were collected, fixed with 1.6% glutaralde-
hyde, post-fixed in 1% OsO4, dehydrated in alcohol series, and
embedded in epoxy resin. Thin sections were contrasted with
uranyl acetate and lead citrate. Preparations were observed either
with a Philips CM12 electron microscope operating at 80 kV (FEI,
Eindhoven, The Netherlands) or with a Jeol 1400 (Tokyo, Japan)
mounted with CCD cameras (Morada, Olympus SIS, Germany).
Samples were analysed with Jeol 1200 XII Philipps electron
microscope [6].
Preparation of Cytoplasmic and Microsomal Fractions
and Detection of PKC Activation
After stimulation with PMA or Acadesine, cells were washed
with wash buffer (proteoExtractH Subcellular Proteome Extraction
KIT, Calbiochem, La Jolla, CA, USA) and pelleted by
centrifugation for 10 min at 300 g. Extraction Buffer I was added
and cells were incubated for 10 min at 4uC under gentle agitation
and centrifugated for 10 min at 800 g. The supernatant contains
the cytoplasmic fraction. Extraction Buffer II was added to the
pellet and cells were incubated for 30 min at 4uC under gentle
agitation. Finally they were centrifugated for 10 min at 5500 g.
The supernatant contains the microsomal fraction was collected.
Cytosolic and Lysosomal fractions were separated by SDS-Page
and transferred onto PVDF membranes which were incubated
with specific anti-PKC a, b, c, h antibodies from BD transduction
laboratories (Franklin Lakes, NJ, USA) [7].
CB Activity Measurement
After stimulation, cells were lysed for 30 min at 4uC in lysis
buffer (0.4 M Na Phosphate PH 6, 150 mM NaCl, 4 mM EDTA,
1 mM PMSF, 10 mg/ml aprotinin and 1% Triton X-100) and
lysates were cleared at 10000 g for 15 min at 4uC. Each assay was
performed with 50 mg of protein prepared from control or
stimulated cells. Cellular extracts were incubated with 60 mMo f
z-RR-AMC as substrate for various times at 37uC. CB activity was
measured by following emission at 460 nm (excitation at 390 nm)
as described earlier [19].
Primary Cells Isolation
Blood samples were collected from patients newly diagnosed for
CML as part of an institutionally approved cellular sample
collection protocol. Informed consent has been obtained according
to institutional guidelines. Mononuclear cells were isolated from
blood samples by density centrifugation (Ficoll-Paque
TM Plus),
washed with PBS, 5% SVF, 2 mM EDTA and resuspended in cell
culture medium (IMDM, 10% fetal bovine serum) and incubated
overnight at 37uC in a 5% CO2 incubator before CD34+ cells
isolation. CML cells were labelled with CD34 microbeads isolated
by magnetic positive selection (StemSep
TM Human CD34
Selection Kit; StemCell, Vancouver, BC, Canada). Purity was
estimated to At least 90% by FACS analysis. Experiments were
performed using a StemSpan
R SFEM medium (StemCell,
Vancouver, BC, Canada) supplemented with 100 ng/ml human
recombinant SCF, FLT3-L and 20 ng/ml human recombinant
IL-3, IL-6 and G-CSF (Peprotech, Rocky Hill, NJ, USA).
Colony Formation Assay
Acadesine was added to K562 cell lines or primary cells (10
3
CD34+ cells/ml) growing in semisolid methyl cellulose medium.
MethoCult H4100 or H4236 were used for cell lines and primary
CD34+ cells respectively (StemCell Technologies Inc., Vancouver,
Canada). Colonies were detected after 10 days of culture by
adding 1 mg/ml of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) reagent and were scored by Image J
quantification software (U.S. National Institutes of Health,
Bethesda, MD, USA).
Confocal Microscopy Experiments
K562 cells were treated with MitoTrackerH Red and Lyso-
trackerH Green for 30 min at 37uC.Then cells were washed with
PBS and cytospun on a slide with CytofunnelH (Thermo Fisher
Scientific Inc., MA, USA). Cells were fixed with paraformaldehyde
3% for 10 min and after fixation and rinsed several times with
PBS. Finally slides were analyzed with Confocal microscope
ZEISS LSM510 META.
Sh-RNA Assays
K562 cells were transfected by electroporation. Cells were
centrifuged at 400 g for 5 min and resuspended in 100 ml of buffer
V containing 2 mg of empty vector or plasmid expression vector
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Cells were electroporated using the T-16 program of the Amaxa
nucleofector (Amaxa, Koln, Germany). 48 h after transfection,
cells were treated with 1 mM acadesine. 48 h latter, cell
metabolism assays were realized and Western Blots were
performed to check extinction of AMPK expression.
si-RNA Assays
siRNA transfections were performed using Lipofectamine
RNAiMAX (Invitrogen). K562 cells were centrifuged at 400 g
for 5 min and resuspended in RMPI with 5% FCS completed with
1 mM sodium pyruvate. Then, cells were transfected with 50 nM
of si-AMPKa1 and si-AMPKa2 or si-Control. After 48 h, cells
were stimulated with 1 mM of acadesine or 1 mM of imatinib.
Two day later, cell metabolism assays were carried out and
Western Blots were performed to check extinction of AMPK
expression.
Tumor Regression Experiments in Nude Mice
Female Nude NMRI Mice (Janvier, Le Genest Saint Ile, France)
were randomized into two experimental groups, each containing
15 animals. Animals in both groups received a 100 ml injection of
5.10
6 K562 leukemia cells on both flanks. When tumors reached
150–200 mm
3, animals were injected intraperitoneally with NaCl
0.9% or acadesine at dose level of 50 mg/kg body weight. The
volume of tumors were measured every 5 days Tumor volume was
calculated according to the mathematical formula:
V=(0.4)*L*(W)
2, (L: Length; W: Width).
May-Gru ¨nwald Giemsa Staining
K562 cells were processed as described previously [6].
Measurement of Apoptosis
After Imatinib or acadesine stimulation, K562 and Ima-R cells
were stained according to manufacturer’s recommended protocol
for Annexin-V-FLUOS Staining Kit (Roche Diagnostics,
Penzberg, Germany).Then, staining cells were analyzed with
cytometer.
Results
Acadesine-Mediated Inhibition of Cell Viability Does Not
Involve Apoptosis
To investigate the effect of acadesine on cell metabolism, we
stimulated different CML cell lines for 48 h with various
concentrations of this compound. Acadesine induced a dose-
dependent decrease of cell metabolism with a maximal effect
around 1 mM in all the CML cell lines tested (Figures 1A, B and
Figure S1 A to C). Therefore, all the forthcoming experiments
were performed with this concentration of acadesine. Importantly,
acadesine also inhibited cell metabolism in imatinib-resistant K562
cells and in Ba/F3 cells carrying the BCR-ABL-T315I mutation
(Figures 1B and Figure S1D). Next, we investigated whether
acadesine exerted its anti-leukemic effect through induction of
apoptosis. As expected, z-VAD-fmk inhibited by 30–40%
Imatinib-mediated loss of cell metabolism in K562 cells at 48 h
[22], whereas it failed to reduce the effect of acadesine (Figure 1C).
Accordingly, and in contrast to Imatinib, acadesine neither
activated caspase 3 (Figure 1D) nor it induced phosphatidyetha-
nolamine externalisation in K562 and other CML cells (Figure S1
E and F). Therefore, we conclude that apoptosis is not required for
acadesine-mediated inhibition of cell metabolism in several well
characterized CML cell lines.
Morphological Analysis of Acadesine-Treated K562 Cells
To gain insight into the anti-leukemic effect of acadesine, we
performed May-Grunwald Gemsa staining of K562 cells. Cells
treated for 48 h with acadesine revealed marked morphologic
modifications, including increase in both cell and nucleus sizes
(Figure S2A). Moreover, accumulation of small to large size
vacuoles was consistently detected in acadesine-treated cells
(Figures 2A and B). These vacuoles were detected as soon as
24 h of acadesine treatment with a maximal accumulation at 72 h
(Figure S2B). Such vesicle formation has been recently document-
ed in K562 cells undergoing autophagy [23]. To characterize
further these vacuoles, we next carried out electron microscopy
experiments. Acadesine increased drastically the number and the
size of the vacuoles present in K562 cells (Figure 2A and B). They
were concentrated in the viscinity of mitochondria and sometimes,
mitochondria were found to be included in vacuoles (Figure 2B).
Larger magnification showed typical lysosomes (Figure 2B) and
autophagosomes (Figure 2B, arrow). To demonstrate further that
these vacuoles do represent autophagosomes and whether
mitochondria inclusion in these putative vesicles reflects an
autophagic process, we incubated K562 cells with acadesine for
48h before addition of the lysosensor-GREEN DN-189 or the
mitotracker red 580 and performed confocal microscopy exper-
iments. In untreated K562 cells, numerous lysozomes and some
mitochondria were seen (Figure 3A). Importantly, while the two
dyes clearly segregated in untreated cells, they colocalized
frequently in acadesine-treated cells. These findings suggest that
acadesine induces mitophagy in CML cell lines. Hence, we
analyzed whether acadesine might induce characteristic hallmarks
of autophagy. During autophagy, LC3-I is cleaved to LC3-II and
subsequently modified through the Atg4-dependent insertion of a
phosphoethanolamine moiety before its insertion into the
membrane of the forming phagophore, a double membrane
required for the recycling of protein aggregates and organelles
[24]. Increased LC3 expression was detected as soon as 6 h after
acadesine treatment, with a maximal accumulation at 24 h
(Figure 3B). In the meantime, acadesine also enhanced the
expression level of P62/SQSTM1 a scaffold protein involved in
the elimination of protein microaggregates through autophagy.
These results were confirmed using the same CML cell lines used
previously (Figure S3 A–C). The observation that acadesine
affected the lysosomal compartment was further substantiated by
the increase in Cathepsin B (CB) activity mediated by this
compound at 48 h in K562 cells (Figure 3C). Importantly,
increased CB activity has been associated with the late steps of
autophagy [25].
The Anti-Leukemic Effect of Acadesine Is Independent on
AMPK Activation
There is accumulating evidence in non-hematopoietic tumors
that the anti-cancerous effect of AMPK activators, including
acadesine,maybe AMPKindependent[26]. To determine whether
acadesine does activate AMPK in CML cells, we analyzed the
phosphorylation status of this kinase in K562 cells using an anti-
phospho-AMPK specific antibody. Acadesine increased AMPK
phosphorylation as soon as 6 h, with a maximal effect at 24 h in
different CML cell lines (Figure 4A). It is well established that
activation of AMPK is associated with inhibition of the m-TOR
pathway leading to ribosomal protein S6 dephosphorylation [27].
Accordingly, acadesine inhibited S6 phosphorylation, in agreement
with the observed time-course of AMPK activation. Of note, this
compound failed to modulate BCR-ABL and Crkl phosphorylation
atthe sametime,indicating thatthe acadesineanti-leukemiceffectis
independent on BCR-ABL. To definitely turn-down the possibility
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knocked-down AMPK protein expression by sh-RNA. Although an
80% decrease in AMPK expression was achieved in K562 cells,
48 h after transfection of the most potent AMPK sh-RNA, this had
no effect on acdesine-mediated loss of cell metabolism in K562 cells
(Figure 4C). Identical results were obtained using a couple of Si-
RNA that inhibits both the a1a n da2 catalytic subunits of AMPK
(Figure 4D). Here again, inhibition of AMPK expression failed to
increase cell viability in the presence of either acadesine or imatinib,
demonstrating that AMPK is not responsible for the loss of cell
metabolism in drug-treated cells (Figure 4E and not shown). Hence,
the anti-leukemic effect of acadesine in CML cells is not mediated
by AMPK.
PKC Activation Mediates the Inhibitory Effect of
Acadesine on Cell Viability
The molecular mechanisms underlying the anti-leukemic effect
of acadesine are not known. To decipher further the mechanism of
action of this compound in CML cells, we analyzed the effect of a
panel of pharmacological agents known to inhibit the main cellular
signaling pathways including p38MAPK, JNK, ERK1/2, PI3K,
mTOR, PKA, PKC and the caspase cascade. Among them, only
GF109293X (GFX), an inhibitor of both classical and new PKC
isoforms prevented the inhibitory effect of acadesine on K562 cell
viability (Figure 5A). To exclude a non-specific effect of GFX we
also used another inhibitor of PKC, namely Ro-32-0432. This
confirmed the role of PKC in mediating the acadesine effect
Figure 1. Acadesine Induces loss of cell viability in an apoptosis independent manner. (A) K562 cells were incubated for 48 h at 37uC with
increasing concentrations of acadesine. Cell metabolism was measured by the XTT assay as described in Materiel and Methods section. Results are
mean6SD of 4 different determinations made in quadruplicate. Error bars=95% confidence intervals. (B) CML cells or Ba/F3 cells (WT or T315I) were
treated with 1 mM acadesine and cell viability was determined using the XTT assay. (C) K562 cells were incubated for 48 h at 37uC with 1 mM
acadesine or 1 mM Imatinib in the presence or absence of 50 mM zVAD-fmk (ZVAD). Cell metabolism was determined as described above. (D) K562
cells were incubated as described in (C). Cells were harvested, washed, and lysed in caspase buffer. Caspase-3 activity was evaluated in quadruplicate
using Ac-DEVD-AMC as substrate. To allow specific assessment of caspase activity, hydrolysis was followed as a function of time in the presence or
the absence of 10 mM Ac-DEVD-CHO. Results, expressed as arbitrary units (a.u.) per mg of proteins are the means6SD of 4 independent experiments
performed in quadruplicate. Error bars=95% confidence intervals.
doi:10.1371/journal.pone.0007889.g001
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cytoplasmic to the microsomal fraction [28,29]. We used this
later feature to analyse the effect of acadesine on the expression of
the four main PKC isoforms found in K562 cells [7,30], namely,
PKCa, b, c and h. 4 h following PMA stimulation, PKCa and b
disappeared from the cytoplasmic fraction, concomitantly to their
redistribution into the microsomal fraction (Figure 5C). Of note,
acadesine also induced, albeit to a lesser extent than PMA, the
relocation of PKCa, b andI c isoforms. The PKC isoforms present
in the microsomal fractions were phosphorylated, reflecting their
active status. Activation of PKCs was detected as soon as 1 h
following acadesine addition, a time point that precedes the onset
of autophagy. Importantly, GFX efficiently inhibited acadesine-
mediated S6 phosphorylation, LC3 accumulation and SQSTM1
expression illustrating the fact that PKC activation is responsible
for induction of autophagy by acadesine in K562 cells (Figure 5D).
Involvement of PKC activation in acadesine-mediated autophagy
was confirmed using electron microscopy, by the inhibitory effect
of GFX on autophagosome and autophagolysosome formation
(Figure S4). In an attempt to identify which PKC was involved in
the effect of acadesine we knock-downed a, b and c. Unfortu-
nately, while specific si-RNA inhibited significantly the expression
of these isoforms, diminution of any of these isoforms alone was
capable to prevent acadesine effect’s on cell viability (not shown),
suggesting that the combination of several isoforms is necessary to
transduce the effect of acadesine.
Figure 2. Acadesine induces vacuole formation and degradation of cytoplasmic material. Electron microscopy images showing
ultrastructural features of a representative control cell (A) and morphological features of autophagy in K562 treated with 1 mM acadesine for 48 h (B).
Cells were observed at different magnification (x2500, x6000 and x25000). L= Lysosome, A= Autophagosome, N= Nuclei, M= Mitochondria, DM=
Double Membrane Vesicle.
doi:10.1371/journal.pone.0007889.g002
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Xenograft Model of K562 Cells
To assess the stability of acadesine we performed clonogenic
outgrowth of K562 cells in methyl-cellulose (Figure 6A). Acadesine
dose-dependently inhibited K562 colony formation at day 10. The
growth inhibitory effect of acadesine was already detected at 0.25
mM and was maximal at 2.5 mM. The same experiments were
performed with purified CD34+ from a CML patient. Acadesine
at 0.5 mM was as potent as 1 mM Imatinib to reduce the number
of colonies capable to grow in methyl-cellulose and no colony were
detected at 1 mM acadesine (Figure 6B). Hence, the anti-leukemic
effect of acadesine on K562 cells and CD34+ progenitor was long-
standing and thus, we decided to test this compound on CML
tumor formation in mice. To this end, we injected nude mice
subcutaneously with 5.10
6 K562 cells on both flanks. After one
week, when tumors reached approximatively 250 mm
3, mice were
randomly separated in two groups. The first one received an
intraperitoneal injection of NaCl 0.9% every day during 2 weeks
whereas the remaining mice were treated with acadesine (50 mg/
kg in NaCl 0.9%). Tumor size was evaluated at days 0, 7, 13, 16
and 20. Acadesine significantly reduced tumor formation in nude
mice (Figure 6C). Statistic analysis of tumor size shows a robust
reduction of 68% at day 16 and 51% at day 20, confirming the
potent anti-leukemic effect of acadesine in vivo.
Figure 3. Acadesine induces hallmarks of autophagy in K562 cells. (A) K562 cells were incubated at 37uC with 1 mM acadesine. After 48 h
cells, were incubated for 30 min with the Mitotracker-Red 580 and the Lysotracker-Green DND-189. They were cytospun on a slide fixed with 3%
paraformaldehyde, mounted on glass slides and analysed by confocal microscopy. (B) K562 cells were incubated at 37uC with 1 mM acadesine for the
indicated times. Whole-cell lysates were prepared, and expression of SQSTM1 and LC3 was visualized by western blotting. Actin was used as loading
control. (C) K562 cells were incubated with 1 mM acadesine for 48 h at 37uC and cathepsin B activity was evaluated in the presence or the absence of
CA-074Me as described in Materials and Methods section. Results, expressed as arbitrary units (a.u.) per mg of proteins are the means6SD of 4
independent experiments performed in quadruplicate. Error bars=95% confidence intervals.
doi:10.1371/journal.pone.0007889.g003
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Acadesine has currently used in phaseI/II for the treatment of
B-CLL [31]. In the present study we evaluated the potential anti-
leukemic effect and the mechanism of action of acadesine on CML
cell lines both in vitro and in vivo. The data presented herein
demonstrate that acadesine exerts a potent anti-leukemic effect on
different CML cell lines. Although acadesine does activate the
AMPK pathway in CML cells, several lines of evidence indicate
that this kinase is not involved in the anti-leukemic effect of
acadesine. Firstly, AMPK knock-down by specific sh-RNA or si-
RNA did not interfere with acadesine-mediated growth arrest and
inhibition of cell metabolism. Secondly, the PKC inhibitors GFX
and R0- efficiently inhibited the antileukemic effect of acadesine,
Figure 4. Inhibition of the acadesine-induced AMPK pathway fails to rescue cell viability. (A) K562 cells were incubated with 1 mM
Acadesine for the times indicated. Cells were harvested, washed and lysed in lysis buffer. Protein samples were separated by electrophoresis and
expression of Phospho-AMPK, AMPK, Phospho-S6 Ribosomal Protein, S6 Ribosomal Protein, phospho-Abl, Abl and phospho-Crkl was visualized by
western blotting. (B) K562 cells were transfected by electoporation with either an empty vector or a plasmid expression vector coding for a sh-RNA
targeting AMPK. 48 h later, cells were treated or not with 1 mM acadesine. Protein samples were prepared and separated by SDS-Page and the
proteins of interest were visualized by western blotting. (C) K562 cells were transfected as in (B) and cell metabolism was measured by the XTT assay
as in Figure 1A. In panels A and B, Actin and HSP90 were used as loading control. (D) K562 cells were transfected with control siRNA or the
combination of a1 and a2 AMPK siRNA. 48 h later, cells were treated with 1 mM imatinib or 1 mM acadesine for 48 h. Finally, cells were lysed and
lysates were analyzed for AMPK extinction. Actin was used as a loading control. (E) Cells were transfected as described above, and cell metabolism
was measured by the XTT assay as in Figure 1A.
doi:10.1371/journal.pone.0007889.g004
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AMPK activator (not shown). Importantly, acadesine activated
several PKC isoforms, including a, b and c in K562 cells.
Altogether, our findings support the involvement of PKC but not
AMPK in the anti-leukemic properties of acadesine. In several
models of leukemia, acadesine has been reported to trigger AMPK
activation, an effect accompanied by an important inhibition of
their proliferation potential. This effect has often been associated
with caspase activation and induction of apoptosis [32,33].
Interestingly, this is clearly not the case in the present study, since
we were unable to detect any increase in caspase activity upon
acadesine stimulation of different CML cell lines. Accordingly,
acadesine also failed to induce apoptosis in the different CML cell
lines used in the present study. Thus, we conclude, that the anti-
leukemic effect of acadesine did not involve induction of apoptosis
in several CML cell lines.
Figure 5. Alteration of leukemic cell viability by acadesine is mediated via PKC activation. (A) K562 cells were incubated with 1 mM
acadesine in the presence of different concentrations of GFX. 48 h later, cell metabolism was measured by the XTT assay. (B) K562 cells were
incubated with 1 mM acadesine in the presence of increasing concentrations of Ro-32-0432 or 5 mM of GFX. 48 h later, cell metabolism was
measured by the XTT assay. (C) K562 cells were incubated with 1 mM acadesine or 20 ng/ml PMA as a positive control of PKC activation. At the times
indicated, cells were harvested, washed and subcellular fractions were prepared. Protein samples were separated by electrophoresis and expression
of PKCa, b, c , h was visualized by western blotting. As expected, HSP60 was found only in the microsomal fraction. (C) Cells were incubated with
1 mM acadesine and treated with or without GFX (5 mM). 48 h later, whole-cell lysates were prepared, and expression of SQSTM1 and LC3 were
visualized by western blotting. Actin was used as loading control. (D) Electron microscopy images showing ultrastructural features of representative
cells in each condition.
doi:10.1371/journal.pone.0007889.g005
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PLoS ONE | www.plosone.org 8 November 2009 | Volume 4 | Issue 11 | e7889Figure 6. Acadesine inhibits tumor growth in nude mice. (A) Acadesine in the 0.25-2.5 mM range was added to K562 CML cell lines growing in
semi-solid methyl cellulose medium (0.5610
3 cells/ml). Colonies were detected after 10 days of culture by adding 1 mg/ml of the MTT reagent and
were scored by Image J quantification software. Results are expressed as the number of colony forming cells by well after drug treatment in
comparison with the untreated control cells (CT). Results are means6SD of 3 different determinations made in triplicate. Error bars=95% confidence
intervals. (B) Various concentrations of acadesine were added to CD34+ cells (10
3 cells/ml) from one CML patient growing in semisolid
methylcellulose medium. After ten days in culture, MTT reagent (1 mg/ml) was added to the cell culture and the number of cell colonies was scored
by the ImageJ quantification software.(C) 5610
6 K562 leukemic cell lines were implanted on both flanks in nude mice. After tumor establishment,
animals received a daily intraperitoneal injection of either acadesine (50 mg/kg body weight in NaCl 0.9%). Results are expressed as the increase in
tumor size as a function of time. The number of tumors was 12 and 14 for mice treated with control medium and acadesine containing medium
respectively.
doi:10.1371/journal.pone.0007889.g006
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PLoS ONE | www.plosone.org 9 November 2009 | Volume 4 | Issue 11 | e7889We used a pharmacological approach to further decipher the
signaling pathways by which acadesine exerts its anti-leukemic
effect. Among the large panel of inhibitors tested, the anti-
proliferative effect of acadesine was prevented only by the PKC
inhibitor GFX. As GFX inhibited both conventional (c-PKC) and
new PKC (n-PKC) isoforms, this finding strongly suggests that c
and/or n-PKC mediate the anti-proliferative effect of acadesine on
CML cell lines. We recently reported that K562 cells expressed
several PKC isoforms [7] including conventional PKC a, b and c
and new PKC e and h Upon phorbol ester stimulation, these
isoforms translocated from the soluble to the microsomal fraction
with subsequent activation [7]. In the present study, we
demonstrated for the first time that acadesine is a potent activator
of the a, b, c PKC isoforms and that the anti-proliferative effect of
acadesine relies on PKC rather than AMPK activation. It has
been recently reported that ischemic preconditioning activates the
AMPK pathway in a PKCe-dependent manner suggesting a
connection between the AMPK and PKC pathways [34]. It was
proposed that PKCe may activate AMPK by phosphorylation but
no evidence of this attractive possibility was presented in this study.
Our results show that acadesine activated simultaneously and
independently these two pathways in CML cell lines and that only
PKC activation was involved in the anti-leukemic effect of
acadesine. The exact mechanisms by which acadesine activates
PKCs is currently unknown and further experiments are needed to
decipher this novel and original signaling pathway.
It is well established that AMPK functions as an intracellular
energy sensor regulating both metabolism and cell proliferation
[35]. Under conditions of reduced nutrient avaibility, autophagy a
process wherein catabolism of intracellular organelles generates
energy allows cell survival. However, prolonged or massive
autophagy can lead to non-apoptotic type II programmed cell
death [36]. We observed that upon acadesine stimulation, K562
cells exhibited no evidence of apoptotic cell death, but finally died
at 48 h from a non-apoptotic mode of cell death. It has been
postulated that the dominant cell death phenotype is determined
by the relative speed of the available cell death programs [37,38].
Although several modes of death can be induced by the same
effector only the most effective one, namely apoptosis is usually
evident. In contrast to this model, acadesine promptly induced
autophagy in CML cells leading to cell death in 24-48 h. We
hypothesized that the death induced by acadesine in CML cells
may represent type II programmed cell death. Confocal and
electron microscopy analysis together with measurement of LC3
accumulation confirmed that acadesine was a potent inducer of
autophagic cell death in different CML cell lines. There are
compelling evidence that acadesine may act as an anti-proliferative
agent in epithelial cancerous cells [32,39,40] and in some leukemic
cell lines [41,42]. Regarding leukemia, acadesine activates and
induces apoptosis in B-CLL [42] and is cytotoxic for childhood
acute lymphoblastic leukemia [41]. In both cases, acadesine was
found to increase AMPK activity but it is not known from these
studies whether or not activation of AMPK is responsible for the
observed anti-proliferative effects. As AMPK is not involved in the
anti-leukemic effect of acadesine in CML cells, it would be
interesting to determine if it is also the case in other leukemia.
Our data established also that treatment of mice with engrafted
CML tumors with acadesine, mediated tumor regression. Such an
anti-tumoral effect of acadesine has already been reported on the
growth of prostatic tumor in nude mice [43], but to our knowledge
our data are the first to demonstrate that acadesine might induce
tumor regression of leukemic cells in vivo. Importantly, our data also
showed that acadesine is very effective in Imatinib-resistant K562 cells
and Ba/F3-T315I cells killing and CD34+ cells from CML patient.
Finally, based on our findings we propose an original model in
which the anti-leukemic effect of acadesine is dependent on PKC-
mediated induction of autophagic cell death but independent of
AMPK activation and apoptosis. The relation between PKC
activation and autophagy is not clear, but PMA through PKCa
activation has been shown to increase the volume of autophago-
somes in hepatocytes [44]. In the same line, we have shown
recently that the phorbol ester and PKC activator PMA promotes
autophagy in K562 cells [45]. This is consistent with the findings
reported herein regarding the effect of acadesine on autophagy.
To the best of our knowledge, our work provides the first
evidence that PKC-mediated induction of autophagy is required
for the anti-leukemic effect of acadesine. Therefore, in addition to
its effect in B-CLL, acadesine might find therapeutical application
in Imatinib-resistant patients.
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Supporting Information
Figure S1 Acadesine Induces loss of cell viability in different
CML cell lines in an apoptotic independent manner. JURL-MK1
cells (A) were incubated for 48 h at 37uC with 1 mM acadesine or
1 mM Imatinib. Cell metabolism was measured by the XTT assay
as described in Figure 1A. K562 parental and Ima-R cells (B)
LAMA-84 cells (C) and Ba/F3-WT and T315I cells (D) were
incubated with increasing doses of acadesine (0.1-2 mM). Cell
metabolism was measured by the XTT assay as described above.
Error bars=95% confidence intervals. K562 (E) and Ima-R K562
cells (F) were incubated for 48 h with either 1 mM Imatinib or
acadesine (0.5 and 1 mM). Detection of apoptotic cells was
determined using annexinV/PI staining and FACS analysis.
Found at: doi:10.1371/journal.pone.0007889.s001 (2.05 MB
TIF)
Figure S2 Acadesine induces significant changes in cell shape
and morphology in K562 cells. (A) K562 cells were incubated for
48 h at 37uC in the presence or the absence of 1 mM acadesine.
Then, cells were cytospun on a slide, air-dried and stained with
May-Gru ¨nwald Giemsa. Slides were observed with an inverted
microscope at different magnifications. (B) K562 cells were
incubated for different times at 37uC in the presence or the
absence of 1 mM acadesine and treated as described in (A).
Found at: doi:10.1371/journal.pone.0007889.s002 (5.90 MB TIF)
Figure S3 Acadesine triggers autophagy and p62/SQSTM1
accumulation in CML cells from different origins. K562 and Ima-
R K562 cells (A), Lama-84 cells (B) and BaF/3 WT and T315I
cells (C) were incubated for 48 h with 1 mM acadesine. Proteins
were extracted and analyzed by western blotting using phos-
phoS6RP, S6RP, LC3 and p62/SQSTM1 antibodies. Actin was
used as a loading control.
Found at: doi:10.1371/journal.pone.0007889.s003 (3.30 MB TIF)
Figure S4 GFX induces inhibition of vacuole formation in
acadesine treated CML cells. Electron microscopy images showing
ultrastructural features of: (A) and (B) untreated K562 cells. (C)
and (D) K562 cells treated with 5 mM GFX (E), (F) and (I) K562
cells treated with 1 mM acadesine (G) and (H) K562 cells treated
with the combination of acadesine (1 mM) and GFX (5 mM).
Found at: doi:10.1371/journal.pone.0007889.s004 (5.02 MB TIF)
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